This is the authors' abstract. We don't add key points for this paper.
Ceftaroline-avibactam and comparator agents were tested by the broth microdilution method against 20,089 isolates consecutively collected in 2010 and 2011 from 75 U.S. medical centers. Ceftaroline-avibactam was active against Enterobacteriaceae (4,908 strains; MIC90, 0.25 μg/ml; highest MIC, 4 μg/ml), including meropenem-nonsusceptible Klebsiella spp. and ceftazidime-nonsusceptible Enterobacter cloacae strains (MIC90, 1 μg/ml for both). Ceftaroline-avibactam was also active against ceftriaxone-nonsusceptible Streptococcus pneumoniae (MIC(90), 0.25 μg/ml) and methicillin-resistant Staphylococcus aureus (MIC(90), 1 μg/ml).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sader et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: